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Background. Up-until-now, the survival and health-related
quality of life of hemodialysis and peritoneal dialysis patients
has only been compared in observational studies. These studies
have reported small and opposing differences between both
modalities. The aim of this study was to compare the outcome
of hemodialysis as initial chronic dialysis treatment with that of
peritoneal dialysis in a randomized controlled trial.
Methods. All new dialysis patients from 38 dialysis centers
in The Netherlands without indications against either modal-
ity were invited to participate. Patients were assigned to start
with hemodialysis or peritoneal dialysis. The primary outcome
was mean quality-adjusted life year (QALY) score. Secondary
outcome was survival.
Results. Due to the low inclusion rate, the trial was prema-
turely stopped after which 38 patients had been randomized: 18
patients to hemodialysis and 20 to peritoneal dialysis. The mean
QALY score in the first 2 years was 59.1 (SD 12) for hemodial-
ysis patients versus 54.0 (SD 19) for peritoneal dialysis patients,
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which constitutes a small difference in favor of hemodialysis
of 5.1 (95%CI −7.3 to 17.6) After 5 years of follow-up, nine
hemodialysis and five peritoneal dialysis patients had died, a
significant difference in survival; hazard ration of hemodialysis
versus peritoneal dialysis of 3.8 (95%CI 1.1 to 12.6). After ad-
justment for age, comorbidity, and primary kidney disease the
hazard ratio was 3.6 (0.8 to 15.4).
Conclusion. Only a small difference in QALY score was ob-
served between patients who started with hemodialysis com-
pared to patients who started with peritoneal dialysis, lending
support for the equivalence hypothesis. The significant differ-
ence in longer-term survival, which favored peritoneal dialysis
in this small group of patients, could be used to posit that inci-
dent dialysis patients might benefit from starting on peritoneal
dialysis.
The occurrence of end-stage renal disease (ESRD)
leads rapidly to death unless renal replacement (RRT) is
started. For the vast majority of adult patients this will be
dialysis treatment. Two major types of dialysis are avail-
able: hemodialysis and peritoneal dialysis. These forms
differ both technically as well as in the type of effort re-
quired from patients. Although medical, social, or logistic
considerations may preclude one of the dialysis forms, for
most patients a well-considered deliberation has to be
made between starting with hemodialysis or with peri-
toneal dialysis. To make an evidence-based decision on
the initial dialysis type, physicians and patients should be
informed about the benefits and risks of the alternative
modalities on outcome. An appraisal of the benefits and
risk should be based on solid evidence
So far, the survival of HD patients and peritoneal dial-
ysis patients has only been compared in observational
studies. Some studies have reported an improved sur-
vival in peritoneal dialysis patients [1–3] whereas oth-
ers have pointed to a survival benefit for hemodialysis
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patients [4–6]. Still other studies concluded that there
was no evidence for a difference between both modalities
[7–11]. Comparisons of the health-related quality of life
in hemodialysis and peritoneal dialysis patients have also
produced small and opposing differences between these
modalities [12–16]. This variability in results can partly
be attributed to methodologic differences, such as type
of statistical models used or amount of adjustment per-
formed, but also to differences in eligibility criteria, in
case-mix, and in length of follow-up [17, 18]. However,
these inconsistent findings could also be the logical re-
sult of an absence of a true difference between both
modalities; in that case, both modalities would perform
equivalent in terms of patient survival and quality of
life.
The aim of the current study was to compare the sur-
vival and quality of life between hemodialysis and peri-
toneal dialysis in a randomized controlled trial among
patients new on dialysis treatment in The Netherlands.
Although the trial was stopped early because of disap-




All new ESRD patients from 38 Dutch dialysis
units were consecutively invited to participate in The
Netherlands Cooperative Study on the Adequacy of
Dialysis (NECOSAD). The aim of this cohort study was
to monitor the quality and adequacy of dialysis treat-
ment in The Netherlands. Patients had to be 18 years
or older with dialysis as the first RRT. Patients with no
medical, social, or logistic objections against hemodialy-
sis or peritoneal dialysis were eligible for the randomized
controlled trial. During the predialysis phase, patients
obtained education about both treatment modalities ac-
cording to usual local care. In this process, the possibility
of a random selection for initial treatment modality was
offered to the patients. The inclusion period was between
January 1997 and August 2000. All medical ethics com-
mittees approved the study, and all invited patients gave
informed consent before inclusion.
Design and procedures
Randomization was performed by central telephone
service. Consenting patients were stratified by institution
and by diabetes mellitus, and were randomly assigned to
initial chronic hemodialysis or peritoneal dialysis treat-
ment by a computer-generated system. A block random-
ization was performed where the size of the blocks varied
randomly.
Due to the nature of dialysis treatment, neither the
nephrologist nor the patient was blind for the assigned
treatment. Treatment of patients participating in the ran-
domized controlled trial was according to usual local care,
so whenever the course of the renal disease required a
change of modality, or if the patient preferred to change
modality, this was realized.
The following data were collected at baseline: age,
gender, primary kidney disease, comorbidity, and a
plasma and 24-hour urine sample. Primary kidney dis-
ease was classified according to the codes of the European
Renal Association–European Dialysis and Transplanta-
tion Association (ERA-EDTA). Comorbidity was de-
fined according to the risk criteria of Khan et al [19]. This
classification relies on a combination of the number of co-
morbidities and age and results in three risk categories:
low, medium, and high.
A plasma sample and a 24-hour urine sample were
obtained simultaneously in a period of 4 weeks around
the date of randomization. Plasma creatinine and plasma
urea levels were determined. Creatinine was analyzed in
the urine sample. Renal function was expressed as crea-
tinine clearance, corrected for body surface area.
Patients completed a generic health assessment in-
strument, the EuroQol, at regular time intervals. The
EuroQol has been developed by the International
EuroQol group as a standardized generic description of
health status [20]. The questionnaire consists of five items
with three response categories. Patients evaluated their
own overall health on a visual analogue scale (VAS-scale)
anchored at 0 (worst imaginable state) and 100 (best
imaginable state). This EuroQol VAS score was obtained
at the start of dialysis, 3 and 6 months later, and every
6 months afterward. Trained local renal nurses distributed
the questionnaire and a return envelope. Patients were in-
structed to complete and return the questionnaire within
1 week.
Statistical analysis
In the design of the present study, a 2-year inclusion
period was followed by 2 years of follow-up. The pri-
mary outcome measure was the mean quality-adjusted
life year (QALY) score in the first 2 years after the start
of dialysis. The quality of the time spent on dialysis was
obtained from the EuroQol VAS scores. Based on these
VAS scores, we calculated the area under the curve from
randomization until 2 years after the start of dialysis treat-
ment, and divided this area under the curve by time
(in years). This resulted in a mean QALY score over
the first 2 years expressed as a QALY-score per year. The
VAS scores at the start of dialysis were taken as repre-
sentative for the period between randomization and start
of dialysis treatment. VAS scores were set to 0 on the day
a patient died. For example, suppose a patient died ex-
actly 1 year after the day of randomization and the mean
VAS score in the first year was 80, the VAS score in the
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second year for this patient was set to 0, resulting in a
mean QALY score over the first 2 years of 40.
Whenever a patient obtained a kidney transplant,
follow-up was ended, as the aim of the study was to com-
pare patients treated with hemodialysis and peritoneal
dialysis. For patients who obtained a transplant within
2 years after randomization, the mean QALY score of
the period from randomization until transplantation was
taken. A Student t test was used to determine the un-
adjusted difference between both groups, whereas multi-
ple linear regression was used to adjust for differences in
baseline characteristics.
Secondary outcome measure was survival. Survival
times were recorded from the day of randomization until
death or censoring. Survival times were considered to be
censored at the date of a kidney transplant, or at the end
of the follow-up period on June 1, 2002.
The study was designed to demonstrate equivalence
between a treatment strategy starting with hemodialysi
compared to a strategy starting with peritoneal dialy-
sis in the first 2 years after the start of dialysis. When
a difference of maximal 10 points in QALY score is con-
sidered as indicating equivalence and a mean QALY
score of 62 points (SD 17.8) is expected in both groups,
50 patients per group would be needed. With this sample
size, we would have a power of 85% with a one-sided a of
5% to reject the null hypothesis that a treatment strategy
commencing with peritoneal dialysis is worse compared
to a strategy starting with hemodialysis, in favor of the
alternative hypothesis that the QALY scores of the two
groups are equivalent.
In addition, unadjusted survival curves for the total
time of follow-up were estimated using the Kaplan-Meier
method. Unadjusted and adjusted hazard ratios were cal-
culated with Cox proportional hazards regression analy-
sis. Hazard ratios were adjusted for age, comorbidity, and
primary kidney disease.
All analyses were initially performed on an intention-
to-treat (ITT) basis. A second on-treatment analysis was
performed, in which survival times were censored 60 days
after a switch to the other modality.
Role of the funding source
The funding source had no role in the collection, anal-
ysis, or interpretation of the data or in the decision to
submit the manuscript for publication.
RESULTS
The total required sample size was calculated to be
100 patients. After an inclusion period of more than
3 years, only 38 patients had been randomized. Since no
dramatic changes in the inclusion rate were expected and
an extension of the inclusion period with another 5 to
 1232 patients screened 
    459 did not fulfill inclusion  
criteria* 
         773 fulfilled  
    inclusion criteria 
 
  735 patients had a preference
for either HD or PD
 
 38 provided consent 
18 patients randomized 20 patients randomized 
 to hemodialysis  to peritoneal dialysis 
 1 started with PD  3 started with HD 
 
 
5 received a kidney transplant 3 received a kidney transplant 
1 changed to PD after  4 changed to HD after  
 starting with HD  starting with PD 
 
18 included in survival analyses 20 included in survival analysis 
13 included in QALY analyses 15 included in QALY analyses 
Fig. 1. Trial profile. Abbreviations are: HD, hemodialysis; PD, peri-
toneal dialysis; QALY, quality-adjusted life years. ∗These patients had
a medical, social, or logistic objection against either hemodialysis or
peritoneal dialysis.
6 years was not considered to be feasible, the steering
group decided to stop inclusion in the summer of 2000.
In 13 centers, 38 patients were included in the random-
ized controlled trial, of which 18 patients were random-
ized to hemodialysis and 20 patients to peritoneal dialysis
(Fig. 1). Baseline characteristics of the patients are pre-
sented in Table 1. Mean age for hemodialysis patients
(62 years) was higher compared to the mean age of the
peritoneal dialysis patients (55 years). In the hemodial-
ysis group, 61% of the patients were male, and in the
peritoneal dialysis group this was 55%. Mean creatinine
clearance was 11.0 mL/min/1.73 m2 for the hemodialysis
group and 11.6 mL/min/1.73 m2 for the peritoneal dialysis
group at the time of randomization.
Follow-up of the patients is presented in Table 2. On av-
erage, patients were randomized nearly 5 months before
the start of dialysis treatment. One year after randomiza-
tion, the vast majority of the patients had started dialysis
treatment. After 2 years, all patients had started dialy-
sis treatment. One patient randomized to hemodialysis
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Table 1. Patient characteristics
Peritoneal
Hemodialysis dialysis
Number of patients 18 20
Age years (number) 62 (11) 55 (12)
Number of male (%) 11 (61%) 11 (55%)
Primary kidney disease (%)
Diabetes mellitus 5 (28%) 4 (20%)
Glomerulonephritis 0 (0%) 2 (15%)
Renal vascular disease 4 (22%) 2 (15%)
Other 9 (50%) 10 (50%)
Khan’s comorbidity score (%)
Low 9 (50%) 9 (45%)
Medium 4 (22%) 7 (35%)
High 5 (28%) 4 (20%)
Plasma creatinine lmol/L (SD) 685 (224) 676 (247)
Plasma urea mmol/L (SD) 32.8 (10.2) 29.0 (9.5)
Creatinine clearance mL/min/1.73 m2 11.0 (9.2) 11.6 (11.2)
(SD)
SD, standard deviation.
Table 2. Follow-up of the patients randomized to hemodialysis (HD)
or peritoneal dialysis (PD)
Years after randomization
Randomized Cumulative
treatment 0 1 2 3 4 5 over 5 years
Number at risk
HD 18 16 12 6 0 —
PD 20 19 18 12 2 0
Number started dialysis
HD 16 2 — — — 18
PD 17 3 — — — 20
Number changed modality
HD 2 0 0 0 0 2
PD 5 1 1 0 0 7
Number transplanted
HD 1 1 3 0 — 5
PD 0 0 3 0 0 3
Number deceased
HD 1 2 2 4 0 9
PD 1 1 1 1 1 5
had started with peritoneal dialysis, whereas three pa-
tients randomized to peritoneal dialysis had started with
hemodialysis. The decision to start dialysis treatment was
made according to local usual care. Five patients switched
modality in the first year after the start of dialysis treat-
ment. Thereafter, no changes in modality were observed.
All hemodialysis patients obtained in-center hemodial-
ysis treatment. In the peritoneal dialysis group, the
majority of the patients received continuous ambulatory
peritoneal dialysis (CAPD) during the complete follow-
up period, two patients started with CAPD and changed
to continuous cycling peritoneal dialysis (CCPD) after
1 year, and two patients received nightly peritoneal dial-
ysis (NPD), of whom one patient changed to CCPD af-
ter 18 months. In total, eight patients received a kidney
transplant; two patients in the first 2 years after random-
ization and another 6 patients received their transplant
in the third year.
Three hemodialysis patients and two peritoneal dialy-
sis patients died within 2 years after randomization. The
mean QALY score in the first 2 years after the start of
dialysis treatment was 59.1 for hemodialysis patients and
54.0 for peritoneal dialysis patients, resulting in a non-
significant difference in favor of hemodialysis patients of
5.1 (95% CI −7.3 to 17.6) (Table 3). After adjustment for
age, comorbidity score, and primary kidney disease, the
difference between hemodialysis and peritoneal dialysis
was 3.1 (−9.9 to 16.1).
Nine hemodialysis patients and five peritoneal dialysis
patients had died after almost 5 years follow-up. This dif-
ference in survival was significant (ITT analysis, log-rank
test statistic, P = 0.02) (Fig. 2). The unadjusted hazard
ratio for hemodialysis versus peritoneal dialysis was 3.8
(95% CI 1.1 to 12.6). After adjustment for age, comor-
bidity score, and primary kidney disease, the hazard ratio
was 3.6 (0.8 to 15.4) (Table 4).
Subsequently, the analyses were repeated after cen-
soring for modality switches in an on-treatment analysis.
During follow-up, two hemodialysis patients had changed
to peritoneal dialysis, whereas seven peritoneal dialysis
patients had changed to hemodialysis. The primary rea-
sons for a switch from hemodialysis to peritoneal dial-
ysis were patients’ preferences. The reasons to change
from peritoneal dialysis to hemodialysis were related
to catheter problems, fecal peritonitis, and one inguinal
hernia.
In the on-treatment analysis, no statistically signifi-
cant differences in mean QALY score was observed. The
QALY score for hemodialysis patients was 59.2 (11.8) and
54.4 (21.9) for peritoneal dialysis patients, a difference of
4.8 (−9.1 to 18.8) (P value = 0.47). Moreover, no statis-
tically significant difference in survival between the pa-
tients randomized to hemodialysis compared to patients
randomized to peritoneal dialysis was observed (log-rank
test statistic, P = 0.12). The unadjusted hazard ratio from
the Cox’ regression was 3.3 (0.7 to 16.0). After adjust-
ing for age, comorbidity and primary kidney disease, the
hazard ratio was 2.2 (0.1 to 47.7, P = 0.63).
DISCUSSION
The aim of this randomized controlled trial was to
demonstrate equivalence between hemodialysis and peri-
toneal dialysis in terms of a mean QALY score. After
2 years of dialysis treatment the mean QALY score of
hemodialysis patients was 5 points higher than the mean
QALY score of peritoneal dialysis patients on a 0 to 100
scale, after adjustment for patients’ characteristics, this
difference became 3 points. These results are not in con-
flict with the equivalence hypothesis, although confidence
intervals are wide.
In terms of overall (unadjusted) survival, we ob-
served a significant difference between hemodialysis and
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Table 3. Mean quality-adjusted life years (QALY) scores in the first 2 years after the start of dialysisa
Randomized treatment
Difference between Adjusted difference
Peritoneal hemodialysis and between hemodialysis
Hemodialysis dialysis peritoneal dialysis and peritoneal dialysisb
QALY score 59.1 (11.7)c 54.0 (18.9)c 5.1 (−7.3 to 17.6)d 3.1 (−9.9 to 16.1)d
P value = 0.41 P value = 0.63
aPresented results are based on the intention-to-treat analyses.
bAdjusted for age, comorbidity, and primary kidney disease.
cMean (SD).
dDifference (95% CI).
















HD 18  16  12    6    0 –
PD 20  19  18  12    2 0 
Fig. 2. Survival of patients randomized to hemodialysis (HD) and peri-
toneal dialysis (PD), intention-to-treat (ITT) analyses.
Table 4. Unadjusted and adjusted hazard ratio’s for mortalitya
Randomized Hazard ratio P
treatment (95% CI) value Adjusted for
Hemodialysis vs. 3.8 (1.1–12.6) 0.03 —
peritoneal dialysis
Hemodialysis vs. 2.9 (0.8–10.1) 0.10 Age
peritoneal dialysis
Hemodialysis vs. 3.6 (0.8–15.4) 0.09 Age, comorbidity,
peritoneal dialysis and primary
kidney disease
aPresented results are based on the intention-to-treat analyses.
peritoneal dialysis patients in favor of peritoneal dial-
ysis patients in the first 4 years of dialysis treatment.
After censoring survival time for modality changes, the
on-treatment analysis, no such difference was observed.
Modality changes were primarily from peritoneal dialysis
to hemodialysis in the first 2 years after starting dialysis
treatment. So, the patients who switched from modality
survived well on the other treatment as the favorable out-
come of peritoneal dialysis decreased after censoring for
treatment change.
The sample size calculated to demonstrate equivalence
was set to 100 patients. We failed to recruit this target
number in the anticipated period. The number of patients
willing to participate was much lower than we expected.
Of all patients screened, 63% had no medical-, social-,
or logistic indication against one of the modalities and
thus was eligible for the randomized controlled trial. Yet,
the vast majority, some 735 patients, refused participa-
tion because of a preference for one of the modalities;
52% of the patients preferred to start with hemodialy-
sis, 48% chose to start with peritoneal dialysis. The low
response rate could affect the external validity of our re-
sults. However, when we compare baseline characteris-
tics of the patients who refused with those of the trial
patients, no differences in age, gender, primary kidney
disease, or comorbidity score were found. Moreover, we
could not observe a difference in clinical characteris-
tics at the start of dialysis, like residual renal function
or serum albumin level, between patients who refused
and those who participated (data not shown). Based on
these parameters, we feel that the observed results are ap-
plicable to patients without contra-indications for either
modality.
Whenever a patient received a kidney transplant,
follow-up was ended. This could have introduced a bias
as more patients randomized to hemodialysis received a
transplant (five patients) compared to peritoneal dialy-
sis patients (three patients), implying less follow-up time
of patients randomized to hemodialysis. All patients who
received a kidney transplant survived until the end of the
follow-up period (June 1, 2002). After including the sur-
vival time on a kidney transplant in the analyses, the dif-
ference in survival between hemodialysis and peritoneal
dialysis patients became smaller, although still in favor
of peritoneal dialysis; adjusted hazard ratio was 3.0 (95%
CI 0.8 to 11.8). So, including survival time on a kidney
transplant did not alter our findings.
Performing a randomized controlled trial to study the
effect of hemodialysis compared to peritoneal dialysis is
difficult to accomplish as both modalities differ much in
the type of effort required from patients. Moreover, af-
ter extensive patient education, it is conceivable that a
number of patients have developed a preference for ei-
ther hemodialysis or peritoneal dialysis. In fact, in this
study 95% of the eligible patients had a preference for
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one of the modalities. Consequently, it turned out to
be very difficult to conduct such a randomized con-
trolled trial. For comparison of both modalities in a larger
number of patients, we might have to rely on well-
conducted observational studies as well. So far, no ran-
domized controlled trial comparing the outcome of both
modalities has been published. Although the current
study was underpowered, we feel that the results from this
randomized controlled trial add to the ongoing debate
about the relative merits of hemodialysis and peritoneal
dialysis [21]. Our results may suggest that a treatment
strategy starting with peritoneal dialysis leads to a more
favorable survival time compared to a strategy starting
with hemodialysis. The favorable survival time of peri-
toneal dialysis was less apparent in the on-treatment anal-
ysis, taking modality changes into account, which were
mostly peritoneal dialysis to hemodialysis switches. The
major reasons for a change to hemodialysis were medi-
cal problems, such as catheter leakage or peritonitis. Yet,
these patients survived well on the other modality as the
favorable outcome of peritoneal dialysis decreased after
censoring for treatment change. We can only speculate
at an explanation for the difference in 5-year survival. A
possible explanation could be a difference in decline rate
of residual renal function between hemodialysis and peri-
toneal dialysis patients, [22, 23] as residual renal function
is an important predictor of survival [24]. In addition, the
results of the current randomized controlled trial seem
to support recent published suggestions in which a treat-
ment strategy starting with peritoneal dialysis has been
promoted [25, 26].
The sample size calculated to demonstrate equivalence
was set to 100 patients. With this sample size, we would
have had a power of 85% with a one-sided a of 5% to
reject the null hypothesis that a treatment strategy com-
mencing with peritoneal dialysis is worse compared to
a strategy starting with hemodialysis, in favor of the al-
ternative hypothesis that the mean QALY scores over
the first 2 years of the two groups are equivalent. Yet,
we recruited only 38 patients. The post hoc power analy-
ses showed that we had an actual power of 36%. Due to
the limited number of included patients, we cannot ex-
clude that both groups of randomized patients differed
at baseline in terms of prognostic factors. The room for
an attempt at statistical adjustment for these factors was
limited due to the low number of patients included. These
possible drawbacks have to be taken into account by the
interpretation of the results of this randomized controlled
trial.
The present randomized controlled trial showed only
a small difference between hemodialysis and peritoneal
dialysis in terms of QALY score over the first 2 years,
lending support for the equivalence hypothesis. In case
of equivalence, other considerations can be used to make
a decision between hemodialysis and peritoneal dialy-
sis. Somewhat surprisingly, a significant larger difference
in survival between hemodialysis and peritoneal dialysis
patients was observed over the first 5 years, in favor of
patients starting with peritoneal dialysis. Although fur-
ther comparative studies are an absolute necessity, the
significant difference in longer-term survival in the ITT
analysis, which favored peritoneal dialysis in this small
group of patients, could be used to posit that incident
dialysis patients might benefit from starting on peritoneal
dialysis.
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